Abstract
Background: Serotonin (5‐hydroxytryptamine: 5‐HT) reduces the coronary blood flow (CBF) as a product of aggregating platelets. Sarpogrelate, a specific 5HT2‐receptor antagonist, has been reported to increase the coronary collateral flow in humans; however, its effect on the microcirculation is still not fully understood.
Hypothesis: This study was undertaken to determine whether sarpogrelate might improve the microcirculation in coronary artery disease (CAD).
Methods: To investigate the effect of sarpogrelate on the microcirculation in CAD, we measured CBF in 15 patients with CAD but no significant stenosis in the left anterior descending artery (LAD). The patients were randomly allocated to two groups, including those receiving oral administration of 200 mg of sarpogrelate (SPG, 8 patients, age 61 ± 6 years) and those receiving no medication (controls, 7 patients, age 57 ± 8 years). Prior to and 1 h after the administration of sarpogrelate, or in controls at 1‐h intervals, the average peak velocity (APV) at baseline and hyperemia was measured by an intracoronary Doppler guidewire. Systemic blood pressure (SBP) and cardiac output (CO) were also measured.
Results: In the patients receiving SPG, the medication significantly increased the baseline (18 ± 9 to 19 ± 10 cm/s, p < 0.05) and maximal APV (55 ± 9 to 64 ± 31 cm/s, p < 0.05). However, no significant changes were observed in SBP and CO after the administration of SPG. In the control group, there were no significant differences in baseline and hyperemic APV.
Conclusion: Sarpogrelate increased both baseline and maximal CBF without changing the systemic hemodynamics. These findings thus support that SPG improves the microcirculation by antagonizing the vasoconstrictive products of the aggregating platelets in CAD.
Keywords: coronary microcirculation; 5HT2‐receptor antagonist; adenosine, nitric oxide
Full Text
The Full Text of this article is available as a PDF (37.8 KB).
References
- 1. Ashton JH, Benedict CR, Fitzgerald C, Raheja R, Taylor A, Campbell WB, Buja LM, Willerson JT: Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73:572–578 [DOI] [PubMed] [Google Scholar]
- 2. Golino P, Piscione F, Willerson JT, Cappelli‐Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M, Chiariello M: Divergent effects of serotonin on coronary‐artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324:641–648 [DOI] [PubMed] [Google Scholar]
- 3. McFadden EP, Clarke JG, Davies JG, Kaski JC, Haider AW, Maseri A: Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324:648–654 [DOI] [PubMed] [Google Scholar]
- 4. Mc Fadden EP, Bauters C, Lablanche J, Quandalle P, Leroy F, Bertrand ME: Response of human coronary arteries to serotonin after injury by coronary angioplasty. Circulation 1993; 88(part 1): 2076–2085 [DOI] [PubMed] [Google Scholar]
- 5. Toda N, Okamura T: Comparison of the response to 5‐carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J Pharmacol Exp Ther 1990; 253:676–682 [PubMed] [Google Scholar]
- 6. Tanaka T, Fujita M, Nakae I, Tamaki S, Hasegawa K, Kihara Y, Nohara R, Sasayama S: Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol 1998; 32:1982–1986 [DOI] [PubMed] [Google Scholar]
- 7. Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG: Understanding the coronary circulation through studies at the microcirculation levels. Circulation 1990; 82:1–7 [DOI] [PubMed] [Google Scholar]
- 8. Takase B, Nagai T, Hakamada N, Katsushika S, Hamada H, Uehata A, Isojima K, Ohtomi S, Ito T, Ohta S, Satomura K, Kurita A, Nakamura H: Assessment of coronary flow reserve using the Doppler FloWire and intracoronary injection of adenosine triphosphate disodium (ATP): Assessment of optimal dosages. Kokyu to Junkan 1996; 44:855–860 (in Japanese) [Google Scholar]
- 9. Zeiher AM, Drexler H, Wollschlager H, Just H: Modulation of coronary vasomotor tone: Progressive endothelial dysfunction with different early stage of coronary atherosclerosis. Circulation 1991; 83:391–401 [DOI] [PubMed] [Google Scholar]
- 10. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki A, Takeshita A: Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993; 91:29–37 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE: Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88:993–1003 [DOI] [PubMed] [Google Scholar]
- 12. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E: Impaired endothelium‐dependent vasodilation of coronary resistance vessels is associated with exercise‐induced myocardial ischemia. Circulation 1995; 91:2345–2352 [DOI] [PubMed] [Google Scholar]
- 13. Lekakis LP, Papamichael CM, Vemmos CN, Voutsas AA, Stamatelopoulos SF, Moulopoulos SD: Peripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms. J Am Coll Cardiol 1998; 31:541–546 [DOI] [PubMed] [Google Scholar]
- 14. Muller JM, Davis MJ, Chilian WM: Integrated regulation of pressure and flow in the coronary microcirculation. Cardiovasc Res 1996; 32:668–678 [PubMed] [Google Scholar]
- 15. Chilian WM, Layne SM: Coronary microvascular responses to reductions in perfusion pressure: Evidence for persistent arteriolar vasomotor tone during coronary hypoperfusion. Circ Res 1990; 66:1227–1238 [DOI] [PubMed] [Google Scholar]
- 16. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium‐derived relaxing factor. Nature 1987; 327:524–526 [DOI] [PubMed] [Google Scholar]
- 17. Jones CJH, Kuo L, Davis MJ, DeFily DV, Chilian WM: Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1995; 91:1807–1813 [DOI] [PubMed] [Google Scholar]
- 18. Minamino T, Kitakaze M, Matsumura Y, Nishida K, Kato Y, Hashimura K, Matsuura Y, Funaya H, Sato H, Kuzuya T, Hori M: Impact of coronary risk factors on contribution of nitric oxide and adenosine to metabolic coronary vasodilation in humans. J Am Coll Cardiol 1998; 31:1274–1279 [DOI] [PubMed] [Google Scholar]
- 19. Ito A, Egashira K, Kadokami T, Fukumoto Y, Takayanagi T, Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A: Chronic inhibition of endothelium‐derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation 1995; 92:2636–2644 [DOI] [PubMed] [Google Scholar]
- 20. Egashira K, Takeshita A: Endothelial function in patients with chest pain and normal coronary arteries. Circulation 1997; 96:1047–1048 [PubMed] [Google Scholar]
- 21. van den Berg EK, Schmitz LM, Benedict CR, Mallory CR, Willerson JT, Dehmer GJ: Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79:116–124 [DOI] [PubMed] [Google Scholar]